Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis
Our retrospective data from two large cohorts suggest that the risk of MACE may be increased among patients with type 2 diabetes taking 5α-reductase inhibitors, potentially driven by increased risk of MI. This supports careful monitoring of macrovascular outcomes when prescribing 5α-reductase inhibitors in this population.
Authors
- William Berthon (ORCID: https://orcid.org/0000-0003-1776-4798)
- R. Andrew
- Luke A. K. Blackbourn (ORCID: https://orcid.org/0000-0003-4234-8040)
- Brian Kennon (ORCID: https://orcid.org/0000-0002-4963-5870)
- John R. Petrie (ORCID: https://orcid.org/0000-0002-4894-9819)
- Robert M. Lindsay
- Paul McKeigue
- Sarah Wild
- Chengsheng Ju
- Scott Cunningham
- Li Wei
- Peter Hanlon
- Ewan Pearson
- Huan Wang
- Naveed Sattar
- Helen Colhoun
- Sam Philip
- Luke A K Blackbourn
- Haolan Tu
- Stuart J McGurnaghan
Institutions
- University of Dundee (GB)
- Institute of Genetics and Cancer (GB)
- University College London (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1093/ehjcvp/pvag003
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00